Table 3.
Univariate cause-specific Cox model for TRM
| Characteristic | HR1 | 95% CI1 | p-value |
|---|---|---|---|
| CAR T cell Product (axi-cel/brexu-cel vs other) | 6.06 | 0.76, 48.6 | 0.090 |
| Age | 1.00 | 0.97, 1.04 | 0.954 |
| Pre-LD KPS (%) | 0.94 | 0.90, 0.98 | 0.004 |
| Pre-LD Ferritin (log10) | 2.25 | 0.88, 5.79 | 0.092 |
| Pre-LD LDH (log10) | 4.23 | 1.26, 14.2 | 0.020 |
| Pre-LD Albumin (log10) | 19.9 | 0.02, 15,974 | 0.381 |
| Pre-LD Bulky Disease | 3.31 | 0.82, 13.4 | 0.093 |
| CRS or ICANS grade at anakinra initiation | 1.20 | 0.63, 2.31 | 0.577 |
| Time to anakinra initiation from CAR T-cell infusion | 1.14 | 1.05, 1.24 | 0.002 |
| Time to anakinra initiation from CRS/ICANS onset | 1.15 | 1.06, 1.26 | 0.001 |
| Anakinra daily dose (mg/kg/day) | 0.41 | 0.22, 0.78 | 0.007 |
1
HR = Hazard Ratio, CI = Confidence Interval
Abbreviations: axi-cel, axicabtagene ciloleucel; brexu-cel, brexucabtagene autoleucel; LDH, lactate dehydrogenase; LD, lymphodepletion; CAR, chimeric antigen receptor; CRS, cytokine release syndrome, ICANS, Immune effector cell-associated neurotoxicity syndrome; TRM, treatment-related mortality